327 related articles for article (PubMed ID: 35905827)
1. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group.
Janez A; Muzurovic E; Stoian AP; Haluzik M; Guja C; Czupryniak L; Duvnjak L; Lalic N; Tankova T; Bogdanski P; Papanas N; Nunes JS; Kempler P; Fras Z; Rizzo M
Int J Cardiol; 2022 Oct; 365():8-18. PubMed ID: 35905827
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.
Madsbad S; Holst JJ
Cardiovasc Res; 2023 May; 119(4):886-904. PubMed ID: 35925683
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
[TBL] [Abstract][Full Text] [Related]
5. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications.
Heile M; Wyne K; Billings LK; Cannon A; Handelsman Y; Shannon M
J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S42-S52. PubMed ID: 30156446
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
Qin J; Song L
BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
Wroge J; Williams NT
Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
[TBL] [Abstract][Full Text] [Related]
9. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(S8 Suppl 1):19-30. PubMed ID: 32756221
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor agonists and cardiovascular outcome trials: An update.
Andrikou E; Tsioufis C; Andrikou I; Leontsinis I; Tousoulis D; Papanas N
Hellenic J Cardiol; 2019; 60(6):347-351. PubMed ID: 30528435
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
15. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
[TBL] [Abstract][Full Text] [Related]
17. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
Al Yami MS; Alfayez OM; Alsheikh R
Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418
[TBL] [Abstract][Full Text] [Related]
18. [A new era for glucagon-like peptide-1 receptor agonists].
Neuville MF; Paquot N; Scheen AJ
Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
20. Effects of GLP-1 receptor agonists on neurological complications of diabetes.
García-Casares N; González-González G; de la Cruz-Cosme C; Garzón-Maldonado FJ; de Rojas-Leal C; Ariza MJ; Narváez M; Barbancho MÁ; García-Arnés JA; Tinahones FJ
Rev Endocr Metab Disord; 2023 Aug; 24(4):655-672. PubMed ID: 37231200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
